Research
Hormonal
Various treatment modalities, including GLP-1 agonists and dual GLP-1/GIP agonists, are reviewed for their effects on hepatic steatosis and fibrosis.
Practitioners should consider these treatment modalities for managing MASLD.
StrongSupportsmedium confidence
We look at the various conventional treatment modalities... as well as new treatment modalities like resmetirom, glucagon like peptide-1 (GLP-1) agonists, and dual GLP-1/GIP agonists for hepatic steatosis and fibrosis.
Why this rating
The claim is based on a review of existing literature.
Source
Treatment Modalities for Hepatic Steatosis and Fibrosis in Type 2 Diabetes: A Review Article
V. Damle et al. · Journal of Diabetology · 2026
review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →